Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

PDL BIOPHARMA, INC. Form 8-K May 13, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 10, 2011

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission

File Number)

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

Delaware	94-3023969
(State or Other Jurisdiction	(I.R.S. Employ

of Incorporation) Identification No.)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

Item 8.01 Other Events.

On May 10, 2011, PDL BioPharma, Inc. (the Company) issued a press release announcing the pricing of an offering of \$135.0 million of its 3.75% Convertible Senior Notes due May 2015. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release, dated May 10, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ Christine R. Larson Christine R. Larson Vice President and Chief Financial Officer

Dated: May 11, 2011

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release, dated May 10, 2011